Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > June 9, 2020 , date of previous bought deal

<< Previous

Bullboard Posts

Next >>

Comment by Hideawayon Feb 17, 2021 5:36pm

177 Views

Post# 32588308

RE:June 9, 2020 , date of previous bought deal

I would be very suprised if we do not drop to close to $6 tomorrow. The market will see this as dilution and, in the absence of positive news, I would not be suprised if we went a bit below $6. Hope not but that is my guess.I would have been much happier if they had used the current upswing and $7 plus to list on nasdaq.Think our run has been derailed for now.

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals